This site uses cookies. By using this site you agree to receiving cookies. View Policy.
Successfully funded
/https://files-crowdcube-com.s3.amazonaws.com/files/pitch_pics/original/202002/blob_538976b40171dffddc7a39637140bc91)
ACTIPH is the UK's first high-alkaline, ionised water. Ionised water was first developed in Japan and approved by their ministry of health in 1965. Since then alkaline water has become one of the fastest-growing categories globally with sales of $883m+ in 2018. By 2023 the market is expected to exceed $4.3bn.
- ACTIPH is pioneering the alkaline water category in UK.
- Major listings include Tesco, Sainsbury's, Ocado, H&B, Wholefoods, BP.
- As of April 2020, exporting to 11 countries including US, UAE, Ireland, Greece, Qatar, and growing.
- Sales of over 150,000 units in February 2020 alone.
The company has received £610,000 of the funds reflected on its progress bar and share certificates will be issued early. This investment is on the same terms offered to the Crowd and the funds will be spent during the campaign.
Idea
ACTIPH Water was founded by Jamie Douglas-Hamilton after his world record breaking row across the Indian Ocean led him to search for the best form of hydration. Supercharged to a pH 9.8, ACTIPH offers hydration with a refreshing taste for people who live an active, balanced lifestyle.
Launched in 2017, we began in the premium and health segments of the market. With proof of concept and strong consumer demand, we moved into major retailers in 2019. Our UK listings include Tesco, Sainsbury's, Ocado, Harrods, Selfridges, Planet Organic, Wholefoodsand more. We also export to 11 countries.
By April 2020, we’d sold over 1.35 million units and amassed 26,300 social media followers along the way.
We bring an added-value product to what has become a very commoditised sector. Our vision is to lead the growth of alkaline waters across Europe and the Middle East, with a market-leading position in all countries built from strong foundations in the UK.
The category is forecast to exceed $4.3bn by 2023, and this funding round will enable us to: increase our sales resource to drive further distribution across Europe; invest in marketing to drive penetration and educate on health benefits; increase production capability and accelerate new product development.
